All News
Curbside Consults (2.16.2024)
Dr. Jack Cush answers audience clinical case questions sent by email or "ask Cush anything". Cases and questions from:
Read Article
Combo IL-23 and TNFi synergistic benefit in UC in the proof-of-concept VEGA trial. More data to come! #RWCS24 @RWCSmtg @RheumNow https://t.co/FgLTR2PBYJ
Dr. Rachel Tate uptoTate ( View Tweet)
Adult vs Juvenile DM by @susanshenoi at #RWCS24 @RWCSmtg @RheumNow
Adults tend to have myalgia, arthralgia, raynauds vs kids with skin ulcerations and vasculopathy https://t.co/1DW2kJsLfa
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. @susanshenoi reviews IIM in juveniles vs adults. Some highlights:
*IBM only in adults
*PM more common in adults
See picture for additional pearls
#RWCS24 @RWCSmtg @RheumNow https://t.co/onUEwkKXBN
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. J. Giles reviews adipose tissue as a source of inflammatory cytokines like TNF, IL-6, IL-1, IL17, etc. #RWCS24 @RWCSmtg @RheumNow https://t.co/AYD9PpwNE6
Dr. Rachel Tate uptoTate ( View Tweet)
Weight loss is associated with reduced systemic inflammation in RA. If only discussing body composition/obesity/adiposity were that easy for our patients, these changes are hard and non-linear. Dr. Jon Giles #RWCS24 @RWCSmtg @RheumNow https://t.co/vrbBHLz6sL
Dr. Rachel Tate uptoTate ( View Tweet)
An updated medication list for diabetes medications with Dr. O. Troum at #RWCS24 @RheumNow @RWCSmtg https://t.co/ZYr5i7PAI9
Dr. Rachel Tate uptoTate ( View Tweet)
#RWCS24 @JointMD @RWCSmtg review the TNFi differences molecularly. @RheumNow https://t.co/6JAnNwwV0n
Dr. Rachel Tate uptoTate ( View Tweet)
"In solid tumors, treat your RA patient as if they do not have a cancer, meaning do not change your therapy if the patient is responding well. Things may get dicey if hematologic malignancy." @RheumNow #RWCS24
I work w/ my onc team to ensure the patient has the needed support.
Dr. Rachel Tate uptoTate ( View Tweet)
Anticardiolipin ab are the most frequent aPL in SLE. Dr. M. Petri #RWCS24 @RWCSmtg @RheumNow https://t.co/cCxhctLTGf
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Petri reviews the 2023 ACR/APS Classification Criteria at #RWCS24 @RheumNow @RWCSmtg https://t.co/FWGsFk02Dn
Dr. Rachel Tate uptoTate ( View Tweet)
Steroids are associated with MACE events in RA. #RWCS24 @RheumNow @RWCSmtg https://t.co/U6ssALNspe
Dr. Rachel Tate uptoTate ( View Tweet)
Controversial MOSAIC results. @JointMD and @RWCSmtg discuss nuances listed below. #RWCS24 @RheumNow https://t.co/aVRJpqHuUM
Dr. Rachel Tate uptoTate ( View Tweet)
Who do you watch closely for developing RA? @RheumNow and @RWCSmtg suggest additional risk factors for ratcheting closer to RA. #RWCS24 https://t.co/lV3I5emn72
Dr. Rachel Tate uptoTate ( View Tweet)
Obese patients more likely to have a lower DMARD response compared to under/normal weighted patients. This still needs to be evaluated on a personal patient level, however, this is an important, layered discussion to have. #RWCS24 @RWCSmtg @rheumnow https://t.co/KIkVXQdcPm
Dr. Rachel Tate uptoTate ( View Tweet)
Oral IL-23 Inhibitor Effective in Psoriasis
The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO).
https://t.co/9GjR6Vx3At https://t.co/tZiykNuzKS
Dr. John Cush RheumNow ( View Tweet)
Mayo study of 1643 #RA pts (Dzduration 7 yrs) found 4 clusters based on # of comorbidities (Cluster 1 [42%] few comorbidities & cluster 4 [7%] > 10). Cluster 1 w/ good prog/survival; but cluster 4 was older, less DMARDs/biologics https://t.co/qAWZoXVWlv https://t.co/g3gMsNj848
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort analysis of 330 psoriasis pts - 83 (25%) developed #PsA after mean of 36 (3.5–114) mos. PsA Predictive factors include being female (OR=3.33), nails involved (OR=5.4), severe PSO (OR=27.4), po systemic Rx prior to PsA (4.1) https://t.co/Hpn6f1EUfD https://t.co/QanJkNi5S6
Dr. John Cush RheumNow ( View Tweet)
Sex Disparities in PsA/SpA
https://t.co/3pmFyo6Ztm https://t.co/zanPiI7GT5
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of non–small cell lung cancer(NSCLC) pts Rx w/ immune checkpoint inhibitor finds that those who develop immune-related AE (irAEs) (n=803) have improved overall survival (23.7 vs 9.8 mos survival; P < .001) https://t.co/yiwJZJU10W https://t.co/fwFFlf7Q6L
Dr. John Cush RheumNow ( View Tweet)